Crestor and Tadalafil Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Raises Questions

Patients prescribed a statin for cholesterol and a PDE5 inhibitor for erectile dysfunction or benign prostatic hyperplasia often worry about pill-to-pill conflicts. That concern is reasonable. Statins as a class carry several well-documented drug interactions, particularly simvastatin and atorvastatin, which depend heavily on CYP3A4 metabolism [1]. Rosuvastatin, however, sits in a pharmacokinetically distinct position among statins.

The rosuvastatin prescribing information notes that approximately 10% of an oral dose undergoes hepatic metabolism, primarily via CYP2C9 with minor CYP2C19 involvement [1]. Tadalafil is cleared almost entirely through CYP3A4 [2]. Because these two drugs do not share a rate-limiting enzyme, the classic CYP-mediated interaction that complicates simvastatin-plus-azole or atorvastatin-plus-macrolide pairings does not apply here. No published pharmacokinetic study has demonstrated a clinically meaningful change in rosuvastatin or tadalafil plasma concentrations when the drugs are co-administered.

Pharmacokinetic Profile: Rosuvastatin

Rosuvastatin is hydrophilic compared with most statins. Its oral bioavailability is approximately 20%, and peak plasma concentration occurs 3 to 5 hours after dosing [1]. Hepatic uptake relies on the organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) transporters rather than CYP-mediated first-pass metabolism [3]. This transporter dependence is the reason rosuvastatin interacts with cyclosporine, certain protease inhibitors, and gemfibrozil, all of which inhibit OATP1B1 or BCRP and can raise rosuvastatin AUC by 2- to 7-fold [1][3].

Tadalafil does not inhibit OATP1B1 or BCRP at therapeutic concentrations. The FDA label for tadalafil lists no statin among its known pharmacokinetic interactions [2]. A 2014 review of PDE5 inhibitor drug interactions published in the British Journal of Clinical Pharmacology confirmed that "PDE5 inhibitors do not significantly alter the pharmacokinetics of HMG-CoA reductase inhibitors" [4].

Pharmacokinetic Profile: Tadalafil

Tadalafil reaches peak concentration in about 2 hours and has a notably long half-life of 17.5 hours, which supports once-daily dosing for BPH at 5 mg or on-demand use at 10 to 20 mg for erectile dysfunction [2]. CYP3A4 converts tadalafil to a catechol metabolite that carries minimal pharmacologic activity [2]. Strong CYP3A4 inhibitors such as ketoconazole increase tadalafil AUC by 312%, while strong inducers like rifampin decrease it by 88% [2].

Rosuvastatin has no known CYP3A4 inhibitory or inducing effect. The rosuvastatin label does not list any capacity to alter CYP3A4 substrate exposure [1]. Co-administration therefore should not change tadalafil clearance.

Pharmacodynamic Considerations

The pharmacodynamic overlap between these two drugs is limited but worth noting. Tadalafil causes mild systemic vasodilation through the nitric oxide/cGMP pathway. In the key trials for BPH (the LVHP studies), tadalafil 5 mg daily lowered mean systolic blood pressure by 1.2 to 4.8 mmHg and diastolic blood pressure by 0.4 to 2.4 mmHg relative to placebo [5]. Rosuvastatin has a minor and inconsistent effect on blood pressure; a 2017 meta-analysis in Hypertension Research (18 RCTs, N=3,263) found that statins reduced systolic BP by about 2 mmHg, with wide confidence intervals crossing zero in many subgroups [6].

For patients already taking antihypertensives, adding both drugs could produce a small additive BP-lowering effect. This is clinically relevant only for individuals with baseline systolic pressure below 90 mmHg or those on multiple vasodilators.

The critical pharmacodynamic warning applies to nitrates, not statins. The tadalafil label states: "Administration of tadalafil to patients who are using any form of organic nitrate, either regularly or intermittently, is contraindicated. Tadalafil potentiates the hypotensive effect of nitrates" [2]. This nitrate contraindication is sometimes conflated with statin therapy, but the two drug classes operate through entirely different vascular mechanisms. Statins do not release nitric oxide or modulate cGMP signaling at clinically relevant levels.

Myalgia and Musculoskeletal Monitoring

Both rosuvastatin and tadalafil include myalgia in their adverse-effect profiles, which can create diagnostic uncertainty if a patient reports new muscle pain after starting the combination.

Rosuvastatin-associated myalgia occurs in roughly 3 to 5% of patients across clinical trials. In the JUPITER trial (N=17,802), musculoskeletal symptoms were reported by 25.7% of the rosuvastatin group versus 24.7% of placebo, a difference that was not statistically significant for serious myopathy [7]. Rhabdomyolysis with rosuvastatin monotherapy is rare, estimated at 0.3 per 10,000 person-years based on FDA Adverse Event Reporting System data [8].

Tadalafil-related myalgia (often described as back pain or limb pain) appeared in 1.2 to 6.5% of patients in the ED trials, dose-dependent and typically resolving within 48 hours [2]. The mechanism is thought to involve PDE11 cross-reactivity in skeletal muscle rather than direct myotoxicity [9].

If a patient on both drugs develops myalgia, the Endocrine Society and ACC/AHA guidelines recommend checking creatine kinase (CK) levels. A CK elevation exceeding 10 times the upper limit of normal warrants statin discontinuation pending evaluation [10]. Isolated back pain that resolves within 24 to 48 hours and occurs around tadalafil dosing is more consistent with PDE5i-related myalgia than statin myopathy.

Hepatic Safety and Monitoring

Rosuvastatin carries a hepatic monitoring recommendation. The ACC/AHA 2018 cholesterol guideline recommends baseline hepatic transaminases (ALT/AST) before starting statin therapy, with repeat testing only if symptoms suggest hepatotoxicity [10]. In JUPITER, persistent ALT elevations exceeding 3 times the upper limit of normal occurred in 0.3% of the rosuvastatin 20 mg group [7].

Tadalafil is hepatically cleared but rarely hepatotoxic. The label does not require routine liver monitoring [2]. For patients with Child-Pugh Class A or B hepatic impairment, tadalafil doses should not exceed 10 mg for on-demand use [2]. Rosuvastatin requires a starting dose of 5 mg in patients with severe renal impairment (eGFR <30 mL/min) and is contraindicated at doses above 10 mg in Asian patients due to higher systemic exposure, per the FDA label [1].

There is no evidence that combining rosuvastatin with tadalafil produces additive hepatotoxicity.

Dose Adjustment: Usually Not Required

Neither the rosuvastatin nor the tadalafil label mandates dose adjustment when the drugs are co-prescribed. The 2023 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies reaffirms that rosuvastatin doses of 5 to 40 mg daily can be used alongside drugs that do not affect OATP1B1 or BCRP transport without modification [11].

For tadalafil, dose adjustment is required only when CYP3A4 inhibitors or inducers are involved. The FDA recommends a maximum tadalafil dose of 10 mg every 72 hours when a potent CYP3A4 inhibitor is present [2]. Rosuvastatin does not meet this criterion.

Exceptions exist for specific populations. Patients with eGFR <30 mL/min should start rosuvastatin at 5 mg and should not exceed 10 mg [1]. Patients taking alpha-blockers alongside tadalafil should be hemodynamically stable on the alpha-blocker before adding the PDE5 inhibitor, as the combination may lower blood pressure additively [2].

When to Be Cautious: High-Risk Scenarios

The combination warrants closer monitoring in three specific clinical contexts.

First, patients taking concomitant CYP3A4 inhibitors (e.g., diltiazem, verapamil, or certain HIV protease inhibitors) should have tadalafil doses reduced per labeling [2]. Some protease inhibitors (lopinavir/ritonavir, atazanavir) also inhibit OATP1B1, which raises rosuvastatin levels [1]. In this triple-exposure scenario, both drugs need dose reduction.

Second, patients on multiple antihypertensives who add tadalafil should monitor blood pressure for 2 to 4 weeks. A standing systolic pressure below 90 mmHg at any follow-up visit justifies re-evaluation.

Third, patients with pre-existing myopathy or those taking other drugs associated with muscle toxicity (fibrates, colchicine, daptomycin) should be counseled to report muscle weakness or dark urine immediately if tadalafil is added to their regimen.

Clinical Bottom Line

Rosuvastatin and tadalafil use non-overlapping metabolic pathways. No dose adjustment is required for the majority of patients. The ACC/AHA 2018 guideline supports monitoring hepatic transaminases at baseline and CK only when symptoms arise [10]. Patients should be counseled that statin-related muscle symptoms differ from the self-limited back pain sometimes caused by tadalafil. Blood pressure monitoring during the first month of combination therapy is a reasonable precaution, especially in patients already receiving antihypertensives. The actual contraindication that matters here is tadalafil plus nitrates, not tadalafil plus statins.